Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04867707 · ClinicalTrials.gov registry record · Phase 2
Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes
A Phase 2 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT04867707 is a Phase 2 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 14 participants.
The verdict
NCT04867707, a Phase 2 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.
Interventions
- DRUG Zanamivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2024-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04867707
The ClinicalTrials.gov registry entry for NCT04867707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zanamivir is the first listed.
NCT04867707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04867707 about?
NCT04867707 is a clinical study titled "Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes". The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.
What is the current status of trial NCT04867707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2021-07-14. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT04867707?
The interventions under investigation include: Zanamivir (DRUG).
Who is sponsoring clinical trial NCT04867707?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.